AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.36 USD
+0.23 (0.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $78.35 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
AZN 78.36 +0.23(0.29%)
Will AZN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
Other News for AZN
AbbVie: Growth Is Still A Better Choice
Astra's breast cancer drug not recommended for NHS use due to price
UK dividends calendar
Fixed-duration CALQUENCE? (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
AstraZeneca: Fixed-duration CALQUENCE study shows improvement in PFS for CLL